Diagnostic and Therapeutic Aspects of Monoclonal Gammopathies of Renal Significance (MGRS): An Update
- PMID: 39767252
- PMCID: PMC11675341
- DOI: 10.3390/diagnostics14242892
Diagnostic and Therapeutic Aspects of Monoclonal Gammopathies of Renal Significance (MGRS): An Update
Abstract
Monoclonal gammopathy of renal significance (MGRS) refers to a group of renal disorders caused by a monoclonal immunoglobulin (MIg), secreted by a non-malignant B-cell clone. Unlike overt multiple myeloma or B-cell proliferation, MGRS does not meet those diagnostic criteria. However, it is associated with significant morbidity, due to severe renal, and sometimes systemic, lesions induced by the MIg. Early recognition is crucial, as chemotherapy to suppress MIg secretion often improves outcomes. The spectrum of renal diseases in MGRS is broad, including both well-known conditions like AL amyloidosis and newly described lesions. Kidney biopsy is essential to determine the specific lesion associated with MGRS and assess its severity. Diagnosis involves integrating morphologic alterations using techniques such as light microscopy, immunofluorescence (IF), electron microscopy, and, in some cases, IF staining for Ig isotypes, immunoelectron microscopy, and proteomic analysis. Additionally, a complete hematologic evaluation, including serum and urine protein electrophoresis, immunofixation, and a serum-free light-chain assay, is necessary.
Keywords: chronic kidney disease; light-chains; lymphoproliferative disorders; monoclonal gammopathies; paraprotein-related renal disease; renal biopsy.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures
References
-
- Dispenzieri A., Katzmann J.A., Kyle R.A., Larson D.R., Melton L.J., III, Colby C.L., Therneau T.M., Clark R., Kumar S.K., Bradwell A., et al. Prevalence and Risk of Progression of Light-Chain Monoclonal Gammopathy of Undetermined Significance: A Retrospective Population-Based Cohort Study. Lancet. 2010;375:1721–1728. doi: 10.1016/S0140-6736(10)60482-5. - DOI - PMC - PubMed
-
- Eisele L., Dürig J., Hüttmann A., Dührsen U., Assert R., Bokhof B., Erbel R., Mann K., Jöckel K.-H., Moebus S. Prevalence and Progression of Monoclonal Gammopathy of Undetermined Significance and Light-Chain MGUS in Germany. Ann. Hematol. 2011;91:243–248. doi: 10.1007/s00277-011-1293-1. - DOI - PubMed
-
- Angioi A., Lepori N., Derudas D., Floris M., Mascia G., Cabiddu G., Pani A. Classification and Management of MGRS Related Diseases. G. Ital. Nefrol. 2023;40:S81. (In Italian) - PubMed
-
- Cao X., Medeiros L.J., Xia Y., Wang X., Thomas S.K., Loghavi S., Li X., Shah J.J., Gustafson S.A., Weber D.M., et al. Clinicopathologic Features and Outcomes of Lymphoplasmacytic Lymphoma Patients with Monoclonal IgG or IgA Paraprotein Expression. Leuk. Lymphoma. 2015;57:1104–1113. doi: 10.3109/10428194.2015.1096357. - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous
